Cross-Sector entity
Of the tracked stories, 2 of 2 also mention Adam Alanoff, the most common co-covered peer. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. We currently track 2 Cross-Sector stories that mention CDMO, all published on February 26, 2026.
2 verified stories tracked
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Adam Alanoff, the most common co-covered peer. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. We currently track 2 Cross-Sector stories that mention CDMO, all published on February 26, 2026. Each carries 2 original sources on average.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CDMO. Shared-story counts are live from our verified record — not editorial picks.
Agilent reported a 4.4% core revenue growth in Q1 2026, driven by a strong 7% uptick in the pharmaceutical sector despite an 8% decline in academic and government markets. The company is navigating margin pressures from new tariffs while leaning into high-growth areas like GLP-1 manufacturing and CDMO services.
Agilent Technologies reported a resilient Q1 2026 with $1.8 billion in revenue, driven by a 7% growth in the pharma sector despite significant headwinds in academic and government funding. While the company faced a 100-basis-point gross margin compression due to rising tariffs and weather disruptions, strong performance in the Agilent CrossLab Group suggests a shift toward service-oriented recurring revenue.
Source: Motley Fool Transcribing (us) · Motley Fool Transcribing (us)
